Amgen Inc (AMGN)
310.14
-2.68
(-0.86%)
USD |
NASDAQ |
May 10, 16:00
310.74
+0.60
(+0.19%)
After-Hours: 20:00
Amgen Cash from Financing (TTM): -2.169B for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -2.169B |
| December 31, 2023 | 21.05B |
| September 30, 2023 | 17.24B |
| June 30, 2023 | 20.84B |
| March 31, 2023 | 20.99B |
| December 31, 2022 | -4.037B |
| September 30, 2022 | -9.546B |
| June 30, 2022 | -8.286B |
| March 31, 2022 | -9.846B |
| December 31, 2021 | -8.271B |
| September 30, 2021 | -5.303B |
| June 30, 2021 | -9.949B |
| March 31, 2021 | -6.552B |
| December 31, 2020 | -4.867B |
| September 30, 2020 | -3.206B |
| June 30, 2020 | -4.267B |
| March 31, 2020 | -11.03B |
| December 31, 2019 | -15.77B |
| September 30, 2019 | -17.41B |
| June 30, 2019 | -17.13B |
| March 31, 2019 | -15.78B |
| December 31, 2018 | -22.49B |
| September 30, 2018 | -21.06B |
| June 30, 2018 | -19.58B |
| March 31, 2018 | -16.18B |
| Date | Value |
|---|---|
| December 31, 2017 | -6.594B |
| September 30, 2017 | -6.582B |
| June 30, 2017 | -4.893B |
| March 31, 2017 | -5.937B |
| December 31, 2016 | -2.599B |
| September 30, 2016 | -1.399B |
| June 30, 2016 | -3.439B |
| March 31, 2016 | -1.147B |
| December 31, 2015 | -3.771B |
| September 30, 2015 | -6.011B |
| June 30, 2015 | -5.066B |
| March 31, 2015 | -4.176B |
| December 31, 2014 | -3.274B |
| September 30, 2014 | 3.695B |
| June 30, 2014 | 6.995B |
| March 31, 2014 | 5.816B |
| December 31, 2013 | 2.726B |
| September 30, 2013 | -2.428B |
| June 30, 2013 | -3.791B |
| March 31, 2013 | -1.801B |
| December 31, 2012 | 419.00M |
| September 30, 2012 | 3.457B |
| June 30, 2012 | -186.00M |
| March 31, 2012 | 457.00M |
| December 31, 2011 | -674.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-17.41B
Minimum
Sep 2019
21.05B
Maximum
Dec 2023
-2.876B
Average
-5.928B
Median
Cash from Financing (TTM) Benchmarks
| Johnson & Johnson | -21.42B |
| Eli Lilly and Co | 2.772B |
| Merck & Co Inc | -5.57B |
| Pfizer Inc | 23.91B |
| Vertex Pharmaceuticals Inc | -625.00M |